Loading clinical trials...
Loading clinical trials...
An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.
Conditions
Interventions
Investigational HIV vaccine dose A
Investigational HIV vaccine dose B
Locations
1
Belgium
Gent University & Hospital, Center for Vaccinology
Ghent, Belgium
Start Date
October 1, 2010
Primary Completion Date
November 1, 2011
Completion Date
November 1, 2011
Last Updated
February 14, 2012
NCT01875588
NCT04929028
NCT07071623
NCT03087253
NCT07199335
NCT05419024
Lead Sponsor
Institut Pasteur
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions